EP4003532
Kristölluð form af 7-klór-2-(4-(3-metoxýasetidín-1-ýl)sýklóhexýl)-2,4-dímetýl-N-((6-metýl-4-(metýlþíó)-2-oxó-1,2-díhýdrópýridín-3-ýl)metýl)bensó[d][1,3]díoxól-5-karboxamíði
:
EP einkaleyfi í gildi á Íslandi:
23.7.2020:
4.9.2024:
20754482.6
:
4.11.2024:
15.12.2024
:
22.7.2040:
22.7.2026:
31.7.2026
:
CRYSTALLINE FORMS OF 7-CHLORO-2-(4-(3-METHOXYAZETIDIN-1-YL)CYCLOHEXYL)-2,4-DIMETHYL-N-((6-METHYL-4-(METHYLTHIO)-2-OXO-1,2-DIHYDROPYRIDIN-3-YL)METHYL)BENZO[D][1,3]DIOXOLE-5-CARBOXAMIDE
23.7.2020
4.9.2024
4.11.2024
15.12.2024
22.7.2026
:
Constellation Pharmaceuticals, Inc.:
470 Atlantic Avenue, Suite 1401, Boston, MA 02210, US
:
BANDA, Alamelu:
Winchester, MA 01890, US
:
GEHLING, Victor, S.:
Somerville, MA 02144, US
:
Árnason Faktor ehf.:
Guðríðarstíg 2-4, 113, Reykjavík,
:
201962878012 P:
24.7.2019:
US
:
US2020043178:
23.7.2020
:
A61P 35/00, C07D 405/14, A61K 31/4433
: 6
: 18.7.2025
: 22.7.2026
: Árnason Faktor ehf.